688046 药康生物
已收盘 09-30 15:00:00
资讯
新帖
简况
药康生物(688046)披露董事会换届候选人提名公告,9月30日股价上涨8.46%
证券之星 · 09-30
药康生物(688046)披露董事会换届候选人提名公告,9月30日股价上涨8.46%
药康生物涨8.46%,中邮证券四周前给出“买入”评级
证券之星 · 09-30
药康生物涨8.46%,中邮证券四周前给出“买入”评级
药康生物(688046)9月24日主力资金净卖出8125.14万元
证券之星 · 09-25
药康生物(688046)9月24日主力资金净卖出8125.14万元
9月24日药康生物跌6.97%,诺安先锋混合A基金重仓该股
证券之星 · 09-24
9月24日药康生物跌6.97%,诺安先锋混合A基金重仓该股
药康生物(688046)披露开立募集资金理财产品专用结算账户公告,9月23日股价上涨2.33%
证券之星 · 09-23
药康生物(688046)披露开立募集资金理财产品专用结算账户公告,9月23日股价上涨2.33%
9月16日药康生物涨5.19%,诺安先锋混合A基金重仓该股
证券之星 · 09-16
9月16日药康生物涨5.19%,诺安先锋混合A基金重仓该股
药康生物涨5.19%,中邮证券二周前给出“买入”评级
证券之星 · 09-16
药康生物涨5.19%,中邮证券二周前给出“买入”评级
9月14日药康生物涨10.17%,诺安先锋混合A基金重仓该股
证券之星 · 09-14
9月14日药康生物涨10.17%,诺安先锋混合A基金重仓该股
药康生物涨10.17%,中邮证券一周前给出“买入”评级
证券之星 · 09-14
药康生物涨10.17%,中邮证券一周前给出“买入”评级
药康生物:可提供一站式临床前评价服务
证券之星 · 09-14
药康生物:可提供一站式临床前评价服务
每周股票复盘:药康生物(688046)召开临时股东会并通过利润分配预案
证券之星 · 09-13
每周股票复盘:药康生物(688046)召开临时股东会并通过利润分配预案
药康生物(688046)披露2026年第一次临时股东会决议公告,9月10日股价下跌3.32%
证券之星 · 09-10
药康生物(688046)披露2026年第一次临时股东会决议公告,9月10日股价下跌3.32%
药康生物:公司将于10月14日召开2026年半年度业绩暨现金分红说明会
证券日报网 · 09-10
药康生物:公司将于10月14日召开2026年半年度业绩暨现金分红说明会
每周股票复盘:药康生物(688046)股东询价转让价格确定为29.17元/股
证券之星 · 08-30
每周股票复盘:药康生物(688046)股东询价转让价格确定为29.17元/股
药康生物(688046)披露股东询价转让定价情况提示性公告,8月26日股价下跌3.86%
证券之星 · 08-26
药康生物(688046)披露股东询价转让定价情况提示性公告,8月26日股价下跌3.86%
药康生物(688046)披露股东向特定机构投资者询价转让股份资格核查意见,8月25日股价上涨1.8%
证券之星 · 08-25
药康生物(688046)披露股东向特定机构投资者询价转让股份资格核查意见,8月25日股价上涨1.8%
每周股票复盘:药康生物(688046)Q2净利增55.68%
证券之星 · 08-23
每周股票复盘:药康生物(688046)Q2净利增55.68%
药康生物(688046)披露2026年半年度报告,8月19日股价下跌10.0%
证券之星 · 08-19
药康生物(688046)披露2026年半年度报告,8月19日股价下跌10.0%
药康生物(688046.SH)发布半年度业绩,归母净利润1.11亿元,同比增长56.28%
智通财经网 · 08-19
药康生物(688046.SH)发布半年度业绩,归母净利润1.11亿元,同比增长56.28%
药康生物(688046)6月30日股东户数0.78万户,较上期减少14.53%
证券之星 · 08-19
药康生物(688046)6月30日股东户数0.78万户,较上期减少14.53%
加载更多
公司概况
公司名称:
江苏集萃药康生物科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2022-04-25
主营业务:
江苏集萃药康生物科技股份有限公司的主营业务是实验动物模型的研发创制、生产销售及相关技术服务。公司的主要产品是商品化小鼠模型、功能药效、模型创制、定制繁育、代理进出口及其他。
发行价格:
22.53
{"stockData":{"symbol":"688046","market":"SH","secType":"STK","nameCN":"药康生物","latestPrice":37.94,"timestamp":1790751600000,"preClose":34.98,"halted":0,"volume":16589266,"delay":0,"changeRate":0.0846,"floatShares":409999999,"shares":409999999,"eps":0.4451,"marketStatus":"已收盘","change":2.96,"latestTime":"09-30 15:00:00","open":34.86,"high":38.78,"low":34.83,"amount":615000000,"amplitude":0.1129,"askPrice":37.95,"askSize":2,"bidPrice":37.94,"bidSize":46,"shortable":0,"etf":0,"ttmEps":0.4451,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":34.98,"symbolType":"stock_kcb","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":38.48,"lowLimit":31.48,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":410186200,"isCdr":false,"pbRate":6.87,"roa":"--","peRate":85.239272,"roe":"4.85%","epsLYR":0.35,"committee":-0.514377,"marketValue":15562000000,"turnoverRate":0.0404,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-10-08。","afterMarket":{"amount":121408,"volume":3200,"close":37.94,"buyVolume":3781,"sellVolume":0,"time":1790753637746,"indexStatus":"已收盘 09-30 15:30:00","preClose":34.98},"floatMarketCap":15562000000},"requestUrl":"/m/hq/s/688046","defaultTab":"news","newsList":[{"id":"2671200044","title":"药康生物(688046)披露董事会换届候选人提名公告,9月30日股价上涨8.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671200044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671200044?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:08","pubTimestamp":1790777298,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘,药康生物报收于37.94元,较前一交易日上涨8.46%,最新总市值为155.62亿元。该股当日开盘34.86元,最高38.78元,最低34.83元,成交额达6.15亿元,换手率为4.04%。近日,江苏集萃药康生物科技股份有限公司披露《关于召开2026年第二次临时股东会的通知》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000037834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671747882","title":"药康生物涨8.46%,中邮证券四周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671747882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671747882?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:34","pubTimestamp":1790757247,"startTime":"0","endTime":"0","summary":"今日药康生物涨8.46%,收盘报37.94元。2026年9月1日,中邮证券研究员盛丽华,徐智敏发布了对药康生物的研报《功能药效+海外拓展持续高增,盈利能力显著提升》,该研报对药康生物给出“买入”评级。公司为动物模型国内领先者,凭借基因编辑模型的高壁垒持续拓展海外市场和重新业务,维持“买入”评级。药康生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000025776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670199634","title":"药康生物(688046)9月24日主力资金净卖出8125.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670199634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670199634?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:22","pubTimestamp":1790295777,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月24日收盘,药康生物报收于35.92元,下跌6.97%,换手率3.29%,成交量13.51万手,成交额4.95亿元。近5日资金流向一览见下表:药康生物融资融券信息显示,融资方面,当日融资买入3901.3万元,融资偿还4558.76万元,融资净偿还657.47万元。药康生物主营业务:实验动物模型的研发创制、生产销售及相关技术服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669905463","title":"9月24日药康生物跌6.97%,诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669905463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669905463?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:37","pubTimestamp":1790239054,"startTime":"0","endTime":"0","summary":"证券之星消息,9月24日药康生物跌6.97%,收盘报35.92元,换手率3.29%,成交量13.51万手,成交额4.95亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共25家,其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669481430","title":"药康生物(688046)披露开立募集资金理财产品专用结算账户公告,9月23日股价上涨2.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669481430","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669481430?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:08","pubTimestamp":1790172506,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘,药康生物报收于38.61元,较前一交易日上涨2.33%,最新总市值为158.37亿元。该股当日开盘37.72元,最高40.3元,最低37.08元,成交额达4.73亿元,换手率为2.98%。公司近日在华泰证券股份有限公司、兴业证券股份有限公司开立了募集资金理财产品专用结算账户,仅用于闲置募集资金现金管理结算,产品到期且无后续使用计划时将及时注销账户。公司已制定风险控制措施,确保募集资金安全,不影响募投项目实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300040441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062696","title":"9月16日药康生物涨5.19%,诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062696","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667062696?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:37","pubTimestamp":1789547869,"startTime":"0","endTime":"0","summary":"证券之星消息,9月16日药康生物涨5.19%,收盘报34.05元,换手率3.03%,成交量12.43万手,成交额4.16亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共25家,其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A目前规模为46.02亿元,最新净值3.6739,较上一交易日下跌0.15%,近一年上涨16.75%。诺安先锋混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600026045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667606417","title":"药康生物涨5.19%,中邮证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667606417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667606417?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:37","pubTimestamp":1789547859,"startTime":"0","endTime":"0","summary":"今日药康生物涨5.19%,收盘报34.05元。2026年9月1日,中邮证券研究员盛丽华,徐智敏发布了对药康生物的研报《功能药效+海外拓展持续高增,盈利能力显著提升》,该研报对药康生物给出“买入”评级。公司为动物模型国内领先者,凭借基因编辑模型的高壁垒持续拓展海外市场和重新业务,维持“买入”评级。药康生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600026043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667597886","title":"9月14日药康生物涨10.17%,诺安先锋混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667597886","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667597886?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:36","pubTimestamp":1789374984,"startTime":"0","endTime":"0","summary":"证券之星消息,9月14日药康生物涨10.17%,收盘报32.82元,换手率3.36%,成交量13.78万手,成交额4.41亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共25家,其中持有数量最多的公募基金为诺安基金的诺安先锋混合A。诺安先锋混合A目前规模为46.02亿元,最新净值3.6286,较上一交易日下跌1.81%,近一年上涨14.3%。诺安先锋混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659417","title":"药康生物涨10.17%,中邮证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659417?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:36","pubTimestamp":1789374978,"startTime":"0","endTime":"0","summary":"今日药康生物涨10.17%,收盘报32.82元。2026年9月1日,中邮证券研究员盛丽华,徐智敏发布了对药康生物的研报《功能药效+海外拓展持续高增,盈利能力显著提升》,该研报对药康生物给出“买入”评级。公司为动物模型国内领先者,凭借基因编辑模型的高壁垒持续拓展海外市场和重新业务,维持“买入”评级。药康生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667598456","title":"药康生物:可提供一站式临床前评价服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2667598456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667598456?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:18","pubTimestamp":1789373890,"startTime":"0","endTime":"0","summary":"证券之星消息,药康生物09月14日在投资者关系平台上答复投资者关心的问题。针对mRNA肿瘤疫苗研发,公司可提供一站式临床前评价服务。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400019597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507818","title":"每周股票复盘:药康生物(688046)召开临时股东会并通过利润分配预案","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507818","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507818?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:37","pubTimestamp":1789234629,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,药康生物报收于29.79元,较上周的30.71元下跌3.0%。本周关注点公司公告汇总:药康生物召开2026年第一次临时股东会,审议通过2026年半年度利润分配预案。江苏集萃药康生物科技股份有限公司于2026年9月10日召开2026年第一次临时股东会,审议通过上述两项议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666913935","title":"药康生物(688046)披露2026年第一次临时股东会决议公告,9月10日股价下跌3.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666913935","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666913935?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:10","pubTimestamp":1789049424,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘,药康生物报收于30.57元,较前一交易日下跌3.32%,最新总市值为125.39亿元。近日,药康生物发布2026年第一次临时股东会决议公告。公告显示,公司于2026年9月10日召开2026年第一次临时股东会,审议通过了《关于公司2026年半年度利润分配预案的议案》和《关于变更公司注册资本、修订公司章程并办理工商变更登记的议案》。律师见证本次会议程序合法,决议有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000041896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666499591","title":"药康生物:公司将于10月14日召开2026年半年度业绩暨现金分红说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2666499591","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666499591?lang=zh_cn&edition=full","pubTime":"2026-09-10 21:31","pubTimestamp":1789047060,"startTime":"0","endTime":"0","summary":"证券日报网讯9月10日,药康生物发布公告称,公司计划于2026年10月14日10:00-11:00举行2026年半年度业绩暨现金分红说明会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-10/doc-inirkcsq7569797.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-10/doc-inirkcsq7569797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VIG","BK0216","BK4585","688046","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010262","title":"每周股票复盘:药康生物(688046)股东询价转让价格确定为29.17元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010262?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:59","pubTimestamp":1788033547,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,药康生物报收于32.5元,较上周的34.35元下跌5.39%。本周,药康生物8月26日盘中最高价报35.8元。根据2026年8月25日询价申购情况,初步确定本次询价转让价格为29.17元/股。本次询价转让拟转让股份已获全额认购,初步确定受让方为17家机构投资者,拟受让股份总数为10,651,781股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792220","title":"药康生物(688046)披露股东询价转让定价情况提示性公告,8月26日股价下跌3.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792220","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662792220?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:55","pubTimestamp":1787738154,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘,药康生物报收于33.16元,较前一交易日下跌3.86%,最新总市值为136.02亿元。公司于近日披露《股东询价转让定价情况提示性公告》。本次询价转让拟转让股份已获全额认购,初步确定受让方为17家机构投资者,拟受让股份总数为10,651,781股。本次询价转让不通过集中竞价交易或大宗交易方式进行,受让方受让股份后6个月内不得转让。本次转让不涉及公司控制权变更,不影响公司治理结构和持续经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600040914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738244","title":"药康生物(688046)披露股东向特定机构投资者询价转让股份资格核查意见,8月25日股价上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738244","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662738244?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:53","pubTimestamp":1787651612,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,药康生物报收于34.49元,较前一交易日上涨1.8%,最新总市值为141.47亿元。近日,药康生物披露《中信证券股份有限公司关于江苏集萃药康生物科技股份有限公司股东向特定机构投资者询价转让股份相关资格的核查意见》。公告显示,中信证券对南京老岩创业投资合伙企业、浙江自贸区谷岩企业管理合伙企业等五家合伙企业向特定机构投资者询价转让股份的资格进行核查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500037714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211340","title":"每周股票复盘:药康生物(688046)Q2净利增55.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211340?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:12","pubTimestamp":1787418732,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘,药康生物报收于34.35元,较上周的40.5元下跌15.19%。本周,药康生物8月19日盘中最高价报41.09元。股本股东变化截至2026年6月30日,药康生物股东户数为7812.0户,较3月31日减少1328.0户,减幅14.53%。业绩披露要点药康生物2026年中报显示,上半年主营收入4.6亿元,同比上升22.61%;归母净利润1.11亿元,同比上升56.28%;扣非净利润9591.76万元,同比上升52.43%。已完成2025年度利润分配,每10股派1.90元,分红总额89,973,400.00元,占当年归母净利润63.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660429586","title":"药康生物(688046)披露2026年半年度报告,8月19日股价下跌10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660429586?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:04","pubTimestamp":1787148262,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘,药康生物报收于36.0元,较前一交易日下跌10.0%,最新总市值为147.67亿元。该股当日开盘39.6元,最高41.09元,最低35.27元,成交额达8.97亿元,换手率为5.85%。近日,江苏集萃药康生物科技股份有限公司披露2026年半年度报告。报告显示,公司2026年上半年实现营业收入459,550,008.70元,同比增长22.61%;归属于上市公司股东的净利润为110,814,393.33元,同比增长56.28%;扣除非经常性损益后的净利润为95,917,570.62元,同比增长52.43%。利润总额为124,269,473.18元,同比增长60.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900042863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660409364","title":"药康生物(688046.SH)发布半年度业绩,归母净利润1.11亿元,同比增长56.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660409364","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660409364?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:37","pubTimestamp":1787139469,"startTime":"0","endTime":"0","summary":"智通财经APP讯,药康生物 披露2026年半年度报告,报告期公司实现营业收入4.6亿元,同比增长22.61%;归属于上市公司股东的净利润1.11亿元,同比增长56.28%;扣非净利润9591.76万元,同比增长52.43%;基本每股收益0.27元;公司拟每10股派发现金红利1.3元(含税)。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660441716","title":"药康生物(688046)6月30日股东户数0.78万户,较上期减少14.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660441716","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660441716?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133742,"startTime":"0","endTime":"0","summary":"证券之星消息,近日药康生物披露,截至2026年6月30日公司股东户数为7812.0户,较3月31日减少1328.0户,减幅为14.53%。在医疗服务行业个股中,药康生物股东户数低于行业平均水平,截至6月30日,医疗服务行业平均股东户数为4.82万户。从股价来看,2026年3月31日至2026年6月30日,药康生物区间涨幅为68.97%,在此期间股东户数减少1328.0户,减幅为14.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791308109004,"stockEarnings":[{"period":"1week","weight":-0.0174},{"period":"1month","weight":0.189},{"period":"3month","weight":0.6076},{"period":"6month","weight":1.3884},{"period":"1year","weight":1.1275},{"period":"ytd","weight":1.4972}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏集萃药康生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"7812人(较上一季度减少14.53%)","perCapita":"52507股","listingDate":"2022-04-25","address":"江苏省南京市浦口区江北新区学府路12号","registeredCapital":"41018万元","survey":" 江苏集萃药康生物科技股份有限公司的主营业务是实验动物模型的研发创制、生产销售及相关技术服务。公司的主要产品是商品化小鼠模型、功能药效、模型创制、定制繁育、代理进出口及其他。","listedPrice":22.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药康生物,688046,药康生物股票,药康生物股票老虎,药康生物股票老虎国际,药康生物行情,药康生物股票行情,药康生物股价,药康生物股市,药康生物股票价格,药康生物股票交易,药康生物股票购买,药康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}